About
Profile
Headquarters
Intraday
High
-
Low
-
52-week
High
-
Low
-
SPRO
...
Available for logged in users only.
The multiple price alert feature will smartly add or remove $1 if your alert was hit.
It's only available if you are logged in, a V.I.P. member or if you are using the AI chrome extension.
Contact us via Twitter if you are interested in trying it out.
- Spero Therapeutics says cash and cash equivalents as of December 31 were about $76.3M
- Spero Therapeutics GAAP EPS of -$0.06 misses by $0.03, revenue of $25.5M beats by $10.53M
- Spero Therapeutics Q3 2023 Earnings Preview
- Spero Therapeutics appoints Esther Rajavelu as CFO
- Spero Therapeutics GAAP EPS of -$0.23 beats by $0.11, revenue of $2.72M beats by $1.64M
- Spero Therapeutics Q2 2023 Earnings Preview
- Spero CEO Ankit Mahadevia to become chairman, Sath Shukla to succeed
- Spero Therapeutics GAAP EPS of -$0.25 beats by $0.08, revenue of $2.07M beats by $0.8M
- Spero Therapeutics Q1 2023 Earnings Preview
- Spero Therapeutics GAAP EPS of $0.55 beats by $0.51, revenue of $47.44M beats by $24.57M
- Spero Therapeutics Q4 2022 Earnings Preview
- Spero Therapeutics Q4 2022 Earnings Preview
- Spero Therapeutics GAAP EPS of -$0.33 misses by $0.03, revenue of $2M misses by $3.42M
- Spero Therapeutics Q3 2022 Earnings Preview
- Spero Therapeutics Q3 2022 Earnings Preview
- Spero stock soars 79% as GSK to pick stake under license deal for UTI antibiotic
- Spero Therapeutics appoints Kamal Hamed MD CMO
- Spero jumps 64% as FDA clarifies future regulatory path for UTI candidate
- Spero Therapeutics GAAP EPS of -$0.87, revenue of $1.99M
- FDA rejects Spero's application seeking approval of its urinary tract infection tablets